Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations

The authors explore how recent advancements in understanding the pathogenesis of preeclampsia, particularly the role of circulating anti-angiogenic factors like sFlt-1 and PlGF, have led to improved molecular diagnostics and potential therapeutic innovations. They emphasize the importance of these developments for better prediction and management of preeclampsia, especially in high-risk populations such as pregnant women with chronic kidney disease. The paper also highlights the need for ongoing scientific research and the inclusion of pregnant women in clinical trials to ensure the safety and efficacy of new treatments.